Outlook Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on Nasdaq under the ticker OTLK. Headquartered in Iselin, New Jersey, United States, the company is focused almost entirely on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation of bevacizumab intended for retinal diseases, led by wet age-related macular degeneration (wet AMD). For investors, this is a classic late-stage biotech profile: highly concentrated, heavily dependent on regulatory milestones, and therefore very sensitive to FDA decisions, clinical readouts and commercial-launch execution. The company’s roots date back to 2010, with operations beginning in 2011. It was later reincorporated in Delaware in 2015 and renamed Outlook Therapeutics, reflecting a strategic pivot toward ophthalmology. Over time, the business has been built around a single core asset and a clear strategic thesis: to offer a standardized, ophthalmic-grade, injectable bevacizumab product for retina specialists. This matters because bevacizumab is already widely used in retinal practice, but often in off-label, repackaged form. Outlook’s objective is to provide an approved formulation that can address quality, labeling and regulatory gaps in that market. The company’s key product is ONS-5010, marketed as LYTENAVA™ in certain jurisdictions. Its primary target indication is wet AMD, although the company has also referenced broader retinal indications such as diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). In practical terms, the commercial opportunity is centered on replacing or supplementing off-label bevacizumab use with an on-label, ophthalmic-specific product. That positioning gives Outlook a differentiated niche, but also exposes it to an intensely competitive anti-VEGF landscape dominated by established branded therapies and low-cost off-label alternatives. Geographically, Outlook Therapeutics now has an important non-U.S. footprint. The company has obtained regulatory authorization for LYTENAVA™ in the European Union and the United Kingdom, and it has indicated that it has begun or is preparing commercial launch activity in select European markets. This international presence is relevant because it offers a potential revenue bridge while the U.S. regulatory process continues. It also provides some real-world commercial validation outside the United States, which is important for a company whose main value driver still lies ahead. Recent developments have been dominated by the FDA process. In 2025, Outlook announced FDA acceptance and later resubmission of its biologics license application, but it subsequently received a complete response letter toward the end of the year. In early 2026, the company said it had requested a Type A meeting with the FDA to discuss the CRL and potential paths forward. That sequence underscores the binary nature of the investment case: the stock remains fundamentally a regulatory catalyst story, with substantial risk, but also meaningful upside if the company can secure a successful U.S. path for its lead asset.